Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis

BACKGROUND: Inexpensive medicines with a long history of use may currently be prescribed off-label for rare indications. Reimbursement is at the discretion of health insurance companies, and may be unpredictable. The example addressed was ephedrine as add-on treatment for myasthenia gravis. Stakehol...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinreich, Stephanie S., Vrinten, Charlotte, Kuijpers, Marja R., Lipka, Alexander F., Schimmel, Kirsten J. M., van Zwet, Erik W., Gispen-de Wied, Christine, Hekster, Yechiel A., Verschuuren, Jan J. G. M., Cornel, Martina C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427624/
https://www.ncbi.nlm.nih.gov/pubmed/28494776
http://dx.doi.org/10.1186/s13023-017-0636-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427624/
https://www.ncbi.nlm.nih.gov/pubmed/28494776
http://dx.doi.org/10.1186/s13023-017-0636-y

Ejemplares similares